Founded in 2003 as an early pioneer in the new field of biomarker services, Synexa Life Sciences has grown to offer a comprehensive range of analytical and advisory services to global biopharmaceutical companies focused on the identification, development, analysis and interpretation of biomarkers in clinical trials and diagnostic validation programs.
Synexa operates through collaborative, risk-sharing partnerships with clients, aiming to deliver insights that significantly improve the quality of decision-making about a drug through each stage in its development.
Synexa is a privately-held company, led by its three founders and a large team of experienced scientists.
Synexa offers deep expertise in biomarker selection and panel design for each phase of clinical development. Our biomarker programs are tailor-made to clients' needs, usually involving considerable up-front scientific collaboration. Our culture is research-based with scientists involved in all lab activities and analysis. This approach is critical to solving challenging problems in new assay development and to the identification of new insights into the clinical pharmacology of the drug. We help clients interpret the results of the biomarker analysis, often in light of the clinical data, to advise on implications for the drug in question.